Technical Analysis for BLCM - Bellicum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 7.95 0.89% 0.07
BLCM closed up 0.89 percent on Wednesday, May 23, 2018, on 45 percent of normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Flat
See historical BLCM trend table...

Date Alert Name Type % Chg
May 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.89%
May 22 Spinning Top Other 0.89%
May 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.11%
May 21 Outside Day Range Expansion 3.11%
May 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.63%
May 18 Inside Day Range Contraction -0.63%
May 18 Overbought Stochastic Strength -0.63%
May 17 Stochastic Sell Signal Bearish -0.50%
May 17 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.50%
May 17 Overbought Stochastic Strength -0.50%

Older signals for BLCM ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of various forms of cancer. Its lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Its preclinical product candidates include BPX-401, a chimeric antigen receptor (CAR-T) product candidate for the treatment of hematological cancers that express the CD19 antigen; BPX-601, a CAR-T product candidate for treating solid tumors overexpressing the prostate stem cell antigen; and BPX-701, a TCR product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Is BLCM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.49
52 Week Low 5.02
Average Volume 1,022,831
200-Day Moving Average 8.6776
50-Day Moving Average 7.4312
20-Day Moving Average 7.4815
10-Day Moving Average 7.977
Average True Range 0.408
ADX 19.62
+DI 24.08
-DI 16.75
Chandelier Exit (Long, 3 ATRs ) 7.142
Chandelier Exit (Short, 3 ATRs ) 7.804
Upper Bollinger Band 8.6001
Lower Bollinger Band 6.3629
Percent B (%b) 0.71
BandWidth 29.903094
MACD Line 0.1896
MACD Signal Line 0.1506
MACD Histogram 0.039
Fundamentals Value
Market Cap 264.15 Million
Num Shares 33.2 Million
EPS -2.94
Price-to-Earnings (P/E) Ratio -2.70
Price-to-Sales 975.18
Price-to-Book 2.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.30
Resistance 3 (R3) 8.30 8.19 8.24
Resistance 2 (R2) 8.19 8.10 8.19 8.22
Resistance 1 (R1) 8.07 8.05 8.13 8.07 8.20
Pivot Point 7.96 7.96 7.99 7.96 7.96
Support 1 (S1) 7.84 7.87 7.90 7.84 7.70
Support 2 (S2) 7.73 7.82 7.73 7.68
Support 3 (S3) 7.61 7.73 7.66
Support 4 (S4) 7.61